What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment

QR Code

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment

The tumor microenvironment (TME) includes immune (T, B, NK, dendritic), stromal, mesenchymal, endothelial, adipocytic cells, extracellular matrix, and cytokines/chemokines/soluble factors regulating various intracellular signaling pathways (ISP) in tumor cells. TME influences the survival/progressio...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Andrea Palicelli, Stefania Croci, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Moira Ragazzi, Magda Zanelli, Alcides Chaux, Sofia Cañete-Portillo, Maria Paola Bonasoni, Alessandra Soriano, Stefano Ascani, Maurizio Zizzo, Carolina Castro Ruiz, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Daniel M. Berney, Jatin Gandhi, Valerio Copelli, Giuditta Bernardelli, Giacomo Santandrea, Martina Bonacini
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	PD-L1 prostate cancer signaling pathways tumor microenvironment target-therapy Biology (General) QH301-705.5 Chemistry QD1-999
Accès en ligne:	https://doaj.org/article/d2e1d8e6f7c7497d859b967c7d899d94
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1
par: Andrea Palicelli, et autres
Publié: (2021)

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)
par: Andrea Palicelli, et autres
Publié: (2021)

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
par: Andrea Palicelli, et autres
Publié: (2021)

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
par: Andrea Palicelli, et autres
Publié: (2021)

Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells
par: Rosanna Di Tinco, et autres
Publié: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
par: Hyun Tae Lee, et autres
Publié: (2017)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
par: Grecea M, et autres
Publié: (2021)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
par: González-Cao M, et autres
Publié: (2015)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
par: LAI Yanliang, et autres
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
par: Laura Jimbu, et autres
Publié: (2021)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
par: Min Yu, et autres
Publié: (2021)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publié: (2021)

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
par: Anna Pawłowska, et autres
Publié: (2021)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
par: Kensuke Kojima, et autres
Publié: (2021)

Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium
par: Masayuki Nakajima, et autres
Publié: (2021)

PD-L1 expression in angiomatoid fibrous histiocytoma
par: Joshua Byers, et autres
Publié: (2021)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
par: Dinoop Ravindran Menon, et autres
Publié: (2021)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
par: Nitin Roper, et autres
Publié: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
par: Olga V. Kovaleva, et autres
Publié: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
par: Miao Wang, et autres
Publié: (2021)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
par: Keller J Toral, et autres
Publié: (2021)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
par: Clemens Hinterleitner, et autres
Publié: (2021)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
par: Naoya Maekawa, et autres
Publié: (2021)

Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
par: Naoya Maekawa, et autres
Publié: (2014)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
par: KE Ping, et autres
Publié: (2021)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
par: Sarah J. Dart, et autres
Publié: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
par: Yixi Zhang, et autres
Publié: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
par: Chunyi Shen, et autres
Publié: (2021)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
par: Yang Hu, et autres
Publié: (2021)

The effect of hypoxia on PD-L1 expression in bladder cancer
par: Vicky Smith, et autres
Publié: (2021)

PD-L1 is an activation-independent marker of brown adipocytes
par: Jessica R. Ingram, et autres
Publié: (2017)

Magneto-nanosensor platform for probing low-affinity protein–protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction
par: Jung-Rok Lee, et autres
Publié: (2016)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
par: Margherita Passariello, et autres
Publié: (2019)

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
par: A. N. Niemeijer, et autres
Publié: (2018)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
par: Peiyi Xie, et autres
Publié: (2021)

Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide
par: Lee GA, et autres
Publié: (2021)

Regulatory Mechanism of PD-L1 Expression in Primary Liver Cancer
par: LI Shenghao, et autres
Publié: (2021)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
par: Ewa Surmiak, et autres
Publié: (2021)